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Background: Cough and sputum are highly prevalent in patients with chronic obstructive
pulmonary disease (COPD). Pulmonary rehabilitation (PR) has shown to be effective in
managing these symptoms. However, the interpretation of the magnitude of PR effects is
hindered by the lack of minimal clinically important differences (MCIDs).
Purpose: This study established MCIDs for the Leicester cough questionnaire (LCQ) and
the cough and sputum assessment questionnaire (CASA-Q), in patients with COPD after PR.
Patients and Methods: An observational prospective study was conducted in patients with
COPD who participated in a 12-weeks community-based PR program. Anchor- (mean
change, receiver operating characteristic curves and linear regression analysis) and distribu-
tion-based methods [0.5*standard deviation; standard error of measurement (SEM);
1.96*SEM; minimal detectable change and effect size] were used to compute the MCIDs.
The anchors used were: i) patients and physiotherapists global rating of change scale, ii)
COPD assessment test, iii) St. George’s respiratory questionnaire and iv) occurrence of an
exacerbation during PR. Pooled MCIDs were computed using the arithmetic weighted mean
(2/3 for anchor- and 1/3 for distribution-based methods).
Results: Forty-nine patients with COPD (81.6%male, 69.8±7.4years, FEV150.4±19.4%predicted)
were used in the analysis. The pooledMCIDs were 1.3 for LCQ and for CASA-Q domains were:
10.6 - cough symptoms; 10.1 - cough impact; 9.5 - sputum symptoms and 7.8 - sputum impact.
Conclusion: The MCIDs found in this study are potential estimates to interpret PR effects
on cough and sputum, and may contribute to guide interventions.
Keywords: COPD, symptoms, pulmonary rehabilitation, patient health questionnaire,
measurement characteristics, statistics
Introduction
Chronic obstructive pulmonary disease (COPD) is a growing global health concern
that poses major burden on individuals, as well as, on economics and social
systems.1–3 Cough and sputum are present in approximately 60% of patients with
COPD4–6 and have been recognized to affect signiﬁcantly and negatively patients’
health-related quality of life (HRQoL).7,8 Nevertheless, these symptoms have been
scarcely explored and underappreciated in COPD research.9–12
Pulmonary rehabilitation (PR) is a well-established non-pharmacological inter-
vention to manage patients with COPD.3,13,14 However, to interpret the magnitude
of the results achieved with PR on symptoms relief, it is important to understand the
minimal clinically important differences (MCIDs) of patient-reported outcome
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measures (PROMs), ie, the smallest change in a measure
score that is subjectively perceived as relevant to the
patient.15–17 Having MCIDs for symptoms-related
PROMs will: aid to guide interventions;18,19 enhance jud-
gement about the clinical relevance and magnitude of the
PR effect15 allow samples size calculations; and contribute
for deﬁning expected endpoints in clinical trials.16,20,21
Thus, establishing MCIDs is of paramount importance
for several stakeholders, from health professionals and
researchers to guideline developers and policymakers.
We estimated the MCID of PROMs that assess symp-
toms of cough and sputum, ie, the Leicester cough ques-
tionnaire (LCQ)22 and the cough and sputum assessment
questionnaire (CASA-Q)23 in patients with COPD, follow-
ing a PR program.
Materials and Methods
Study Design and Participants
An observational prospective study, part of a larger trial (3R:
Revitalising pulmonary rehabilitation – NCT03799666 on
ClinicalTrials.gov) was conducted in accordance with the
Declaration of Helsinki. Ethical approval was obtained from
the Ethics Committee for Health of the Administração
Regional de Saúde do Centro (Ref. 73/2016) and from the
National Committee for Data Protection (no. 7295/2016).
Prior to enrolment and data collection, a written description
of the study was provided to every participant, who then
signed an informed consent.
Patients were recruited via clinicians at Centro
Hospitalar do Baixo Vouga and primary healthcare centers
of the center region of Portugal during January 2019 and
enrolled a community-based PR program. Patients were
eligible if diagnosed with COPD,3 and clinically stable
over the previous month, ie, no hospital admissions or
exacerbations and no change in medication for the cardi-
orespiratory system. Exclusion criteria included the pre-
sence of other respiratory diseases or any clinical
condition that precluded participants of being involved in
a community-based PR program, ie, signs of cognitive
impairment or presence of a signiﬁcant cardiovascular,
neurological or musculoskeletal disease.
Data Collection
Data were collected before (T0) and after 12 weeks of PR
(T1). Sociodemographic (age, gender), anthropometric
(height and weight to compute body mass index-BMI) and
clinical data (smoking status, medication, number of
exacerbations, hospitalizations or emergency admissions in
the past year) were ﬁrst obtained. The severity of comorbid
diseases was recorded and scored according to Charlson
Comorbidity Index (CCI): i) scores of 1–2; ii) scores of
3–4; and iii) scores ≥5.24 The modiﬁed British medical
research council questionnaire (mMRC) was used to assess
functional dyspnea,25 the COPD assessment test (CAT)26 to
evaluate the impact of the disease and the St. George’s
respiratory questionnaire (SGRQ) to assess HRQoL.27
The LCQ was used to evaluate cough-related quality of
life. The LCQ is a 19-items scale organized in 3 domains
(physical, psychological and social).22 Each domain has
a score ranging from 1 to 7 and the total score varies from
3 to 21.22 Higher scores express a better cough-related
quality of life and less impact of cough.22 The LCQ has
shown to be a valid, reliable and responsive instrument,
namely in COPD.22,28–30
The CASA-Q was used to assess cough and sputum
symptoms, based on its reported frequency and severity,
and impact on daily life activities.23 CASA-Q is a 20-item
questionnaire containing 4 domains: cough symptoms,
cough impact, sputum symptoms and sputum impact.23
All items are rescored and summed, achieving a score
ranging from 0 to 100 for each domain, with higher scores
indicating fewer symptoms and less cough and sputum
impact.23 The CASA-Q has shown to be valid, reliable
and responsive in patients with COPD.23,31,32
The global rating of change scale (GRC)33 was admi-
nistered using an 11-point Likert scale ranging from −5
(much worse) to +5 (much better).33 Participants were
asked to rate their perceived amount of change in cough
and sputum after the PR program, compared to the initial
assessment.
Intervention
All participants completed a 12-weeks community-based
PR program, with two exercise training sessions per week
and one psychoeducational session every two weeks, in 6
primary healthcare centers and in the Lab3R-Respiratory
Research and Rehabilitation laboratory of the School of
Health Sciences, University of Aveiro. Further information
regarding the intervention has been published elsewhere.34
Data Analysis
Statistical analysis was performed using IBM SPSS
Statistics, version 24 (IBM Corporation, Armonk, NY,
USA) and plots created using GraphPad Prism, version 7
(GraphPad, San Diego, CA, USA) and MetaXL 5.3
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(EpiGear International, Queensland, Australia). The level
of signiﬁcance was set at 0.05. The analysis included only
participants that adhered to at least 65% of PR sessions (ie,
participated in at least 8 weeks of PR).3,35
Changes in PROMs from T0 to T1 were analyzed with
paired t-test orWilcoxon signed-rank tests, accordingly to data
normality veriﬁed with the Kolmogorov–Smirnov test. Floor
or ceiling effects (more than 15% of the patients scoring at the
bottom or top)36 were checked. Outlier’s analysis was per-
formed (ie, inspection of extreme points on the plotted graphs
of the variables studied) and, when present, were excluded.37
MCIDs were calculated for the LCQ and CASA-Q.
Since a gold standard to determine the MCID has not
been established, concurrent comparisons of different
methods were performed, integrating both anchor-based
and distribution-based approaches.19,38 The ﬁnal MCID
for each measure was pooled by calculating the arithmetic
weighted mean with the MCID generated by each anchor-
and distribution-based method, which were then intro-
duced into the MetaXL39 to create the MCIDs'plots.
Anchor-based methods were weighed more than distribu-
tion methods (ie, 2/3 against 1/3).19,21,38,40
Minimal Important Clinical Differences
Anchor-Based Methods
Four anchor-based approaches were applied: i) patients
referencing – GRC; ii) physiotherapists referencing –
GRC; iii) questionnaire referencing – CAT and SGRQ
and iv) criterion referencing – occurrence of an exacerba-
tion, as following described.
(i) A change of 2 points or more in the patients’ GRC
scale was considered clinically meaningful
change.33 Thus, patients were categorized into
two groups, those rating ≥2 and those rating <2
points in the GRC.
(ii) Physiotherapists that conducted the exercise ses-
sions were asked to judge about patients’ change
in cough and sputum using a GRC. A change ≥2
was used as the cut-off point for improvement.33
Physiotherapists answered the GRC questions
prior to assessing patients.
(iii) Changes in the LCQ and CASA-Q scores were
anchored against changes in the CAT total score
and in the SGRQ total score. The MCIDs of CAT
(2 points) and SGRQ (4 points) were used to
discriminate between patients.41,42
(iv) Having had an exacerbation during PR.18
The presence of a signiﬁcant and moderate associa-
tion (≥0.3) between the change in the PROM and the
anchor was a requirement to proceed with the MCID
calculation.38 Correlations were assessed using
Pearson’s or Spearman’s coefﬁcients and scatter plots
were generated.
To calculate the MCID according to patients, phy-
siotherapists and questionnaire referencing, three methods
were used: i) the mean change, ie, the absolute difference
between the two means of the PROM score (T1 and T0),
calculated for patients who achieved the MCID established
for the anchor17,19 ii) receiver operating characteristic
(ROC) curves [the area under the curve (AUC) of
a ROC≥0.7 was considered adequate43–45 and the closest
point to the left corner, where speciﬁcity (SP) and sensi-
tivity (SN) are both optimized was considered the optimal
cut-off point] and iii) linear regression analysis, with the
anchor change score being used as an independent
variable.19
As for the criterion referencing, the difference in the
baseline score between patients who experienced an
exacerbation and those who did not was considered the
MCID.18,46 Independent t-tests or Mann–Whitney tests,
depending on data normality, were used.
Distribution-Based Methods
To calculate the MCID, ﬁve distribution-based methods
were used: i) 0.5 times standard deviation (SD);47 ii)
standard error of measurement (SEM);16 iii) 1.96 times
SEM;47 iv) minimal detectable change (MDC)47 and v)
effect size (ES)48 (Table 1).
Table 1 Distribution-Based Methods to Estimate the Minimal
Clinically Important Difference
Method MCID Calculation
0.5SD 0.5*SDT0
SEM SDT0 √(1-r)
1.96SEM 1.96*(SDT0√(1-r))
MDC 1.96 x SEM x √2
ES (meanT1 – meanT0)/
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðSD2T1 þ SD2T0Þ=2
q
ESNP IzI/(√n)
Notes: The test–retest reliability coefﬁcients used were: LCQ ICC=0.92,28 CASA-Q -
ICC cough symptoms =0.77, ICC cough impact =0.88, ICC sputum symptoms =0.80 and
ICC sputum impact =0.82.23
Abbreviations: MCID, minimal clinically important difference; SEM, standard error
measurement; SD, standard deviation; r, test–retest reliability coefﬁcient; MDC,
minimal detectable change; ES, effect size; ESNP, nonparametric effect sizes; T0,
baseline; T1, after the pulmonary rehabilitation program; z, statistic test; n, number
of total matched pairs.
Dovepress Rebelo et al
International Journal of Chronic Obstructive Pulmonary Disease 2020:15 submit your manuscript | www.dovepress.com
DovePress
203
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
13
7.
16
8.
16
 o
n 
14
-F
eb
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ESwere interpreted as small (≥0.2),medium (≥0.5) or large
(≥0.8).48 ES greater than 0.2 were considered to be minimally
clinically/subjectively important.48 After combining both
anchor- and distribution-based methods and pooling the ﬁnal
MCID for each PROM, the corresponding percentage of
change was calculated. Furthermore, we used the pooled
MCID value to compute the matching ES,19 using this
formula:
MCIDES¼ MCIDpooled=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðSD2T1þSD2T0Þ=2
q
.
Results
Sample Characterization
A ﬂow diagram of the forty-nine patients included in the
study is provided in Figure 1.
At baseline, no differences were observed between the
included patients and drop-outs (p>0.05). Patients’ char-
acteristics are summarized in Table 2.
At baseline, all PROMswere completed by the forty-nine
participants, except for the CASA-Q. Data for CASA-Q was
8 drop-outs during PR due to:
Lack of time (n=3)
AECOPD with hospitalization 
(n=2)
Non-COPD health-related 
reasons (n=2)
Unprovided reasons (n=1)
6 primary health care centers
Respiratory Research and 
Rehabilitation Laboratory 
63 patients with COPD 
55 patients with COPD completed PR
6 excluded due to:
<65% adherence to the PR 
program (n=6)
49 patients with COPD included
Figure 1 Flow diagram of participants with chronic obstructive pulmonary disease included in the study.
Abbreviations: COPD, chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; PR, pulmonary rehabilitation.
Rebelo et al Dovepress
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not possible to collect from eight participants, due to data
collection commencement prior to obtaining the authoriza-
tion to use the scale from the author. Additionally, one
participant failed to complete the LCQ at the follow-up
appointment. As missing data from CASA-Q and LCQ
were completely unrelated to questionnaires scores, disease
and symptoms severity, or patients’ adherence to PR (no
statistical signiﬁcant differences were present between the 8
patients with missing data on CASA-Q and the remaining 41
patients for GOLD stages/groups, adherence to PR, SGRQ
and CAT scores), they were considered missing-completely-
at-random.49,50 Thus, we chose to use the listwise deletion
method to handle missing data, since this is the most fre-
quently used method and is known for producing unbiased
results.49,50 After the PR programme, signiﬁcant improve-
ments were found for CAT, SGRQ, LCQ and CASA-Q
cough impact dimension. Baseline and post-PR scores can
be found in Table S.1. Thirty-seven (75.5%) patients
improved beyond the MCID of 2 points established for the
CAT and 31 (63.3%) above the 4 points in the SGRQ. Only
cough and sputum impact dimensions of CASA-Q demon-
strated a ceiling effect, at T0 and T1. After the PR programs,
56.2% and 60.4% of the participants perceived
Table 2 Sample Characterization (n=63)
Characteristics Patients
Included (n=49)
Drop-Outs
(n=14)
p-value
Age, years 69.8±7.4 64.4±13.1 0.154
Gender, male n (%) 40 (81.6) 9 (64.3) 0.169
BMI, kg/m2 26.4±4.9 27.7±5.4 0.410
Smoking status, n (%) 0.554
Current 8 (16.3) 4 (28.6)
Former 31 (63.3) 7 (50.0)
Never 10 (20.4) 3 (21.4)
Packs/year 40.0
[26.0–70.0]
35.0
[15.8–75.4]
0.573
Exacerbations/yeara 1.0 [0.0–1.0] 1.0 [0.0–3.0] 0.142
AECOPD
hospitalisations,a n (%)
4 (8.2) 2 (14.3) 0.292
Duration of hospitalizations
(days)
9.3±4.0 10.5±9.5 0.923
COPD-related
emergencies,a n (%)
16 (32.7) 5 (35.7) 0.463
Lung function (post-
bronchodilator)
FEV1, 1.3±0.5 1.3±0.5 0.769
FEV1, %predicted 50.4±19.4 53.6±20.2 0.589
FEV1/FVC, % 49.9±13.5 54.6±11.8 0.247
GOLD stages, n (%) 0.996
I 6 (12.2) 2 (14.3)
II 17 (34.7) 5 (35.7)
III 22 (44.9) 6 (42.9)
IV 4 (8.2) 1 (7.1)
GOLD groups, n (%) 0.280
A 8 (16.3) 3 (21.4)
B 32 (65.3) 6 (42.9)
C 0 (0.0) 0 (0.0)
D 9 (18.4) 5 (35.7)
CCI, n (%) 0.781
Mild 5 (10.2) 2 (14.3)
Moderate 26 (53.1) 6 (42.9)
Severe 18 (36.7) 6 (42.9)
Medication, n (%)
Bronchodilators
SABA 6 (12.2) 1 (7.1) 0.451
SAMA 3 (6.1) 0 (0.0) 0.292
LABA 7 (14.3) 3 (21.4) 0.745
LAMA 18 (36.7) 7 (50.0) 0.747
LAMA/LABA
combination
14 (28.6) 3 (21.4) 0.568
ICS 10 (20.4) 1 (7.1) 0.206
ICS/LABA combination 20 (40.8) 7 (50.0) 0.580
LTRA 3 (6.1) 2 (14.3) 0.331
Xanthines 9 (18.4) 3 (21.4) 0.823
Expectorants 6 (12.2) 1 (7.1) 0.577
Antibiotics 1 (2.0) 0 (0.0) 0.540
(Continued)
Table 2 (Continued).
Characteristics Patients
Included (n=49)
Drop-Outs
(n=14)
p-value
mMRC 2 [1.0–3.0] 2 [1.0–3.0] 0.791
CAT 17.2±7.8 14.6±7.6 0.287
SGRQ (Total score) 45.6±20.4 40.0±20.3 0.341
LCQ 16.6±3.5 18.6±3.2 0.063
CASA-Q
Cough symptoms 66.7 [41.7; 83.3] 87.5
[66.7; 91.7]
0.068
Cough impact 71.9 [56.3; 93.8] 89.1
[71.9; 100.0]
0.132
Sputum symptoms 66.7 [50.0; 83.3] 75.0 [58.3;
91.7]
0.437
Sputum impact 79.2 [62.5; 95.8] 87.5
[79.2; 100.0]
0.117
Notes: Values are presented as mean±standard deviation or median [interquartile
range], unless otherwise stated. aPast-year.
Abbreviations: PR, pulmonary rehabilitation; BMI, body mass index; AECOPD,
acute exacerbation of chronic obstructive pulmonary disease; FEV1, forced expira-
tory volume in one second; FVC, forced vital capacity; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; CCI, Charlson comorbidity index; SABA, short-
acting beta-agonists; SAMA, short-acting muscarinic antagonist; LABA, long-acting
beta-agonists; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid;
LRTA, leukotriene receptor antagonist; mMRC, modiﬁed medical research council
questionnaire; CAT, COPD assessment test; SGRQ, St George’s Respiratory
Questionnaire; LCQ, Leicester cough questionnaire; CASA-Q, Cough and Sputum
Assessment Questionnaire.
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improvements (GRC) in their cough (2.0, [0.0–3.0]) and
sputum (2.0, [0.0–4.0]), respectively. Physiotherapists
reported improvements in cough for 51% (2.0, [0.0–3.0]),
and in sputum for 55.1% (2.0, [0.0–2.0]) of their patients.
Minimal Clinically Important Differences
After checking for outliers, three participants were
excluded from the LCQ analysis. No differences were
found between the baseline characteristics of the included
patients and the outliers (p>0.05). No outliers were found
in the CASA-Q analysis.
Resume tables of the correlation values between changes
in the PROM and changes in the anchors (Table S.2) and the
MCID achieved with the mean change method (Table S.3)
can be found in Supplementary materials. It was not possible
to use the criterion referencing method to compute the
MCIDs since no signiﬁcant differences were observed
between patients who experienced an exacerbation and
those who did not (Table S.4). In our sample, only mild to
moderate exacerbations occurred.
Leicester Cough Questionnaire
Changes in the LCQ correlated signiﬁcantly with changes
in patients’ GRC for cough symptoms (r=0.340). No other
correlations were found (Table S.2).
The MCID established for the LCQ using the mean
change according to patients’ GRC was 1.4 (Table 3). It
was not possible to use ROC statistics to compute the
MCID, since the AUC generated was not signiﬁcant.
Using linear regression, the estimated MCID for the
LCQ was 0.7 (Figure S.1).
The distribution-based methods for the LCQ, and the
overall MCID pooled statistics are presented in Table 3.
The pooled MCID for the LCQ was 1.3 (Figure 2).
Cough and Sputum Assessment Questionnaire
Changes in CASA-Q cough symptoms domain correlated
signiﬁcantly with changes in SGRQ (s=−0.322), in CAT
(r=−0.378) and with patients’ GRC for cough (s=0.317).
Changes in CASA-Q cough impact domain correlated
signiﬁcantly with patients’ GRC for cough (s=0.464).
Changes in CASA-Q sputum domains, both symptoms
and impact, correlated signiﬁcantly with changes in
SGRQ (s=−0.398 and r=−0.407, respectively). No other
correlations were found (Table S.2).
The MCID derived from the mean change methods
were: i) 9.3, 9.1 and 9.9 for cough symptoms with
SGRQ, CAT and patients’ GRC, respectively; ii) 11.8 for
cough impact; iii) 7.7 for sputum symptoms, and iv) 6 for
sputum impact (Table 3).
Using ROC statistics, the AUCs generated for CASA-Q
cough symptoms domain showed adequate discrimination
between those improving above and below the MCID for
SGRQ (AUC=0.70; 95% CI 0.54 to 0.86; p=0.031) and for
CAT (AUC=0.79; 95% CI 0.62 to 0.97; p=0.005) (Figure 3).
The AUCs obtained for the CASA-Q cough impact (patient’s
GRC: AUC=0.74; 95% CI 0.59 to 0.90; p=0.008) and spu-
tum symptoms (SGRQ: AUC=0.72; 95% CI 0.56 to 0.88;
p=0.019) were also able to distinguish between patients who
improved from those who did not (Figure 3). The AUCs’
discrimination ability was not acceptable for CASA-Q spu-
tum impact using SGRQ and for CASA-Q cough symptoms
using patients’ GRC for cough as anchors (ie, AUC<0.7).
According to the ROC analysis, the MCID found were 4.2
for both cough and sputum symptoms and 4.7 for cough
impact.
Using linear regression, the estimated MCID for the
cough symptoms domain was 1.6 and for sputum impact
domain was 2.2 (Figure S.2).
The distribution-based methods for the CASA-Q and
the overall MCID pooled statistics are presented in Table
3. Pooled MCID for the CASA-Q subscales were 10.6 for
cough symptoms; 10.1 for cough impact; 9.5 for sputum
symptoms and 7.8 for sputum impact (Figure 4).
Discussion
This study estimated a pooled MCID of 1.3 for the LCQ.
The pooled MCIDs established for CASA-Q domains
were: 10.6 for cough symptoms; 10.1 for cough impact;
9.5 for sputum symptoms and 7.8 for sputum impact.
The pooled MCID found for LCQ matched previous
estimates for patients with chronic cough, ie, 1.3 points.51
Nevertheless, higher MCIDs (from 2 to 3 points) have
been suggested,52–54 using a GRC with a period recall of
6 months,52 increasing the recall risk of bias,19,46 and
including patients with acute cough only.53,54 Higher
levels of baseline severity (e.g., acute cough) usually
lead to greater improvements,19,20,47 which result in larger
MCIDs. Moreover, studies have involved pharmacological
interventions only, whilst our study reports on PR. Since
PR demands more from patients, expectations of beneﬁts
and improvements are often higher, producing larger effect
sizes when compared to medication, thus, generating lar-
ger MCIDs.55
The pooledMCIDs for each CASA-Q domain were similar.
Although CASA-Q emerged as a good tool to discriminate
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between patients above and below the anchor’s MCIDs, the
ceiling effect observed was notorious; thus, its MCIDs should
be interpreted with caution. Scores close to the end of the scale,
limit the amount of potential change, affect responsiveness and
consequently the establishment of the MCIDs.19 Presence of
chronic cough was not an inclusion criterion of our study. This
Table 3 Anchor and Distribution-Based Methods Used to Compute the Minimal Clinically Important Difference of Patient-Reported
Outcome Measures Assessing Cough and Sputum
LCQ CASA-Q
Cough Symptoms Cough Impact Sputum Symptoms Sputum Impact
Mean change
SGRQ – 9.3 (2.3 to 16.4) – 7.7 (−1.5 to 16.8) 6.0 (−0.7 to 12.7)
CAT – 9.1 (3.9 to 14.4) – – –
Patient’s GRC 1.4 (0.7 to 2.2) 9.9 (2.6 to 17.3) 11.8 (3.7 to 19.8) – –
ROC
SGRQ – 4.2
SN=68%; SP=75%
– 4.2
SN=80%; SP=60%
–
CAT – 4.2
SN=61%; SP=80%
– – –
Patient’s GRC – – 4.7
SN=67%; SP=75%
– –
Linear regression
SGRQ – 1.6 (−3.4 to 6.6) – – 2.2 (−1.5 to 6.0)
CAT – – – – –
Patient’s GRC 0.7 (−0.9 to 2.4) – – – –
Distribution methods
0.5*SD 1.7 11.5 11.2 11.4 10.3
SEM 1.0 11.0 7.8 10.2 8.7
1.96SEM 1.9 21.6 15.2 20.0 17.1
MDC 2.6 30.5 21.5 28.2 24.2
ES 0.21 0.23 0.19 0.09 0.12
Pooled MCID 1.3 10.6 10.1 9.5 7.8
% of change 6.8 10.6 10.1 9.7 7.8
MCID ES 0.50 0.45 0.45 0.40 0.35
Notes:Values arepresentedasmeanand95%conﬁdence intervals.%of changewas computedwithineach scale range.TheMCIDESare computed as theMCIDvaluedividedby thepooledSD.
Abbreviations: LCQ, Leicester cough questionnaire; CASA-Q, Cough and Sputum Assessment Questionnaire; GRC, global rating of change; CAT, COPD assessment test;
SGRQ, St George’s Respiratory Questionnaire; ROC, receiver operating characteristic curves; SD, standard deviation; SEM, standard error measurement; MDC, minimal
detectable change; ES, effect size; MCID, minimal clinically important difference; SN, sensitivity; SP, speciﬁcity.
Figure 2 Plot of the pooled MCID for the Leicester cough questionnaire. The plot represents the MCID estimates derived in this study, and where appropriate the
estimates include the 95% conﬁdence interval (n=45).
Abbreviations: LCQ, Leicester cough questionnaire; GRC, Global rating of change; SD, standard deviation; SEM, standard error measurement; MDC, minimal detectable change.
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may explain the observed ceilings effects and why impact of
cough and sputum in the HRQoL of our participants was com-
parable to other studies enrolling patients with COPD,31,56 but
different (our sample scored better) from studies considering
patients with chronic cough only.28,57,58
Although previous research has showed a relationship
between CAT and cough and sputum,59,60 in our study an
association was veriﬁed only with cough. However, association
was explored with mean changes, while previous studies have
focused on absolute scores.59,60 Nevertheless, correlations
between changes in SGRQ and changes in CASA-Q cough
and sputum dimensions were found (Table S.2). These ﬁndings
further establish the impact of cough and sputum onHRQoL of
patients with COPD, as previously demonstrated,7,59–64 and
emphasise the urge for assessing and implementing tailored
interventions to manage these symptoms.
It was not possible to use the physiotherapists’ GRC, prob-
ably due to the well-known lack of agreement on symptoms
perception between patients with COPD and health
professionals.65 Moreover, the non-signiﬁcant differences in
baseline symptoms between patients who experienced an
AECOPD and those who did not, hindered the use of this
variable in the anchor-based approach. In our sample, only
mild to moderate exacerbations3 occurred and during PR,
patients were closely monitored; therefore, exacerbations were
promptly identiﬁed and tackled, thus enhancing a faster
recovery.66 Exacerbations were managed as follows: patients
were referred to their clinician, who adjusted their pharmaco-
logical therapy, and were instructed to follow the symptoms
management strategies taught during educational sessions of
PR (energy conservation techniques, postures to relieve dys-
pnoea and active cycle of breathing techniques).34 As soon as
Figure 3 Receiver operating characteristic curves to discriminate between patients with COPD above and below the MCID established for the anchors for the CASA-
Q domains (n=41) using the: (A) SGRQ for cough symptoms domain; (B) CAT for cough symptoms domain; (C) patients' global rating of change for cough impact; and (D)
SGRQ for sputum symptoms.
Abbreviations: CASA-Q, cough and sputum assessment questionnaire; SGRQ, St. George Respiratory Questionnaire; CAT, COPD assessment test; GRC, Global rating of
change; AUC, area under the curve.
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the contagious risk was controlled and patients felt capable they
were encouraged to return to PR (around 7 to 15 days).67When
patients re-integrated the PR programme the training load was
readjusted to their physical condition.
This study has some limitations that need to be acknowl-
edged. First, the presence of ceiling effects in the CASA-Q
might have biased the results. Secondly, our sample wasmainly
composed of patients with moderate to severe COPD.
Therefore, the established MCIDs might not be generalizable
to all patients and should be interpreted with caution in patients
with mild or very severe COPD. Since MCIDs are inﬂuenced
by disease severity,19,20,47 we recommend interpreting PROMs
changes within the MCIDs ranges provided by the different
methods and not limiting it to the absolute proposed value.
Finally, this study is integrated in a larger trial,34 therefore,
a speciﬁc sample size calculation to establish MCIDs was not
performed, which might have underpowered this study for its
goal. Nevertheless, similar samples sizes have been used to
establish MCIDs in other studies,40,68,69 and the fact that all
MCIDs fell within the recommended range of 6 to 10% change
in the scale range, which corresponded to a desirable effect size
of 0.2 to 0.5,19,38,48 strengthens the validity of our estimates.
Moreover, to our best knowledge, this is the ﬁrst study to
provide MCIDs estimations for LCQ and CASA-Q in patients
with COPD; thus, we believe that our MCIDs estimates can be
useful for health professional and policy makers, ensuring they
are used with caution and in accordance with each clinical
context. To conﬁrm our MCIDs estimates, future studies in
this area with larger sample sizes are still required.
An important strength of our study is that MCIDs were
computed through a combination of methodologies, including
a wide range of anchor and distribution-based approaches. In
addition, the pooled method selected allowed to attribute
a higher weight to anchor than distribution-based methods,
following the recommendations for establishing MCIDs.19,38
Standardization of community-based PR programs in terms of
structure, intensity, frequency, duration and progression, as
recommended,13 minimised the heterogeneity of intervention,
assuring that theMCIDs proposed are valid and suitable for PR.
Conclusion
In summary, this study suggests that improvements of 1.3 in
the LCQ, 10.6 in the cough symptoms, 10.1 in cough impact,
9.5 in sputum symptoms and 7.8 points in the sputum impact
dimensions of CASA-Q are clinically relevant for patients
with COPD, following a PR program. These estimates have
the potential to be used to interpret clinical relevance, as
thresholds for the intervention effectiveness and to inform
future studies regarding sample calculation.
Data Sharing Statement
Data sets used and/or analysed during the current study are
available from the corresponding author on reasonable
request.
Figure 4 Plot of the pooled MCID for the cough and sputum assessment questionnaire (CASA-Q): (A) CASA-Q cough symptoms; (B) CASA-Q cough impact; (C) CASA-
Q sputum symptoms and (D) CASA-Q sputum impact. The plots represent the MCID estimates derived in this study.
Abbreviations: CASA-Q, cough and sputum assessment questionnaire; SGRQ, St. George Respiratory Questionnaire; CAT, COPD assessment test; GRC, Global rating of change;
ROC, receiver operating characteristic; SD, standard deviation; SEM, standard error measurement; MDC, minimal detectable change; MCID, minimal clinically important difference.
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